Three months earlier than an expected update on a deal, Becton, Dickinson and Co. reported its biosciences and diagnostic ...

Manufacturing issues are the latest problem for Ultragenyx Pharmaceutical Inc. to solve after last week’s disappointment in a phase III study to treat brittle bones. The U.S. FDA gave the company a ...

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease with limited treatment options. IPF is thought to result from repeated microinjuries to aging lung tissue, triggering ...

Loss of synapses and dysfunctional synapses in a region-specific way is important in Alzheimer’s. It’s actually the strongest correlate of cognitive decline, far more so than plaques and tangles, ...

Multiple sclerosis (MS) is an immune-mediated inflammatory disease characterized by demyelination and degeneration in the ...

Nearly six years after Ichnos Sciences Inc. launched operations, a subsidiary of the now-named Ichnos Glenmark Innovation ...

At first blush, the brain’s extracellular matrix (ECM) seems like the opposite of synaptic plasticity. Plasticity is the ...

When injured, the human skin is repaired through a wound-healing process that forms fibrotic scar tissue. Scarring burdens ...

The U.S. FDA has granted orphan drug designation to Klotho Neurosciences Inc.’s secreted-Klotho (s-KL) promoter, gene and ...

Shanghai Circode Biomed Co. Ltd. is set to begin clinical trials of HM-2002, a circular RNA (circRNA)-based drug for ischemic heart disease, having gained IND clearance in China Jan. 10 and the U.S.

Sensorium Therapeutics Inc. has reported that the U.S. FDA has cleared the IND application for SNTX-2643 (SENS-01), its lead ...

Researchers from IMEC, the Netherlands’ OnePlanet Research Center in Wageningen, filed for protection of an inexpensive, ...